The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

Novo Nordisk recently made headlines petitioning FDA to stop the compounding of its blockbuster GLP-1 products so it can sell its patented ...

The Hims & Hers planned Super Bowl ad buy – and the content of that ad – is noteworthy, but not because it violates any regulations. Indeed, the ad generally complies with federal law and U.S. Food ...

Expanding market reach to drive organic revenue growth without equity dilutionCollaborating with AI-driven health assessments and customized ...

Avoiding a second trial, a former pharmaceutical rep who prosecutors said generated more than $10 million in wrongful insurance reimbursements pleaded guilty Tuesday to perjury in U.S. District Court.